Breaking News Instant updates and real-time market news.

CRAY

Cray

$29.80

0.22 (0.74%)

, HPE

HP Enterprise

$14.55

0.12 (0.83%)

09:03
05/17/19
05/17
09:03
05/17/19
09:03

Fly Intel: Pre-market Movers

HIGHER: Cray (CRAY), up 16% after the company announced an agreement under which Hewlett Packard Enterprise (HPE) will acquire it for $35 per share in cash, in a transaction valued at approximately $1.3B, net of cash... Under Armour (UAA), up 3% after JPMorgan analyst Matthew Boss upgraded the stock to Overweight from Neutral and raised his price target for the shares to $29 from $23. After meeting with management including CEO Kevin Plank, Boss says the clear tone from the top was "controlled confidence" in the brand direction with "disciplined" fiscal 2020 global top- and bottom-line growth acceleration... Achillion (ACHN), up 10% after announcing interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab... Matinas BioPharma (MTNB), up 3% after BTIG analyst Robert Hazlett initiated shares with a Buy rating and $5 price target. UP AFTER EARNINGS: Applied Materials (AMAT), up 2%. DOWN AFTER EARNINGS: Deere (DE), down 5%... Pinterest (PINS), down 17%... Baidu (BIDU), down 14%. LOWER: ADMA Biologics (ADMA), down 3% after a 11.25M share secondary offering priced at $4 per share.

CRAY

Cray

$29.80

0.22 (0.74%)

HPE

HP Enterprise

$14.55

0.12 (0.83%)

DE

Deere

$145.97

1.16 (0.80%)

PINS

Pinterest

$26.01

-2.66 (-9.28%)

BIDU

Baidu

$138.50

-13.95 (-9.15%)

ADMA

ADMA Biologics

$4.32

-0.15 (-3.36%)

UA

Under Armour

$19.45

0.5 (2.64%)

UAA

Under Armour

$22.04

0.68 (3.18%)

ACHN

Achillion

$3.05

0.005 (0.16%)

MTNB

Matinas BioPharma

$0.94

0.0228 (2.48%)

AMAT

Applied Materials

$44.28

2.78 (6.70%)

  • 17

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 11

    Jun

  • 09

    Jul

  • 17

    Jul

  • 17

    May

CRAY Cray
$29.80

0.22 (0.74%)

05/08/19
CHLM
05/08/19
NO CHANGE
Target $36
CHLM
Buy
Cray price target raised to $36 from $31 at Craig-Hallum
Craig-Hallum analyst Chad Bennett raised his price target for Cray to $36 from $31 as largest win in company history eclipses earnings. The analyst also notes that Shasta is on track for Q4, which should drive multi-year acceleration of revenue growth with Slingshot offering valuable optionality on the stock. Bennett reiterates a Buy rating on the shares.
HPE HP Enterprise
$14.55

0.12 (0.83%)

04/09/19
MSCO
04/09/19
NO CHANGE
MSCO
Nutanix helped by HP Enterprise partnership, says Morgan Stanley
Morgan Stanley analyst Katy Huberty kept an Overweight rating and $53 price target on Nutanix (NTNX) after the company signed a new distribution agreement with HP Enterprise (HPE), which the analyst said is "another catalyst in building investor confidence that Nutanix can re-accelerate growth in 1H FY20 after a weak pipeline of new customers drove a miss last quarter." Huberty noted that Nutanix's partnerships with server OEMs now expose the company to about 19.7% of the server market, up from around 7% without the HP Enterprise deal.
04/11/19
FBCO
04/11/19
INITIATION
Target $14
FBCO
Underperform
HP Enterprise initiated with an Underperform at Credit Suisse
Credit Suisse analyst Matt Cabral started coverage of HP Enterprise with an Underperform rating and a $14 price target. The analyst cited fading IT spending tailwinds, with focus returning to building risks on largest and high-margin segments.
03/12/19
UBSW
03/12/19
DOWNGRADE
Target $13
UBSW
Sell
HP Enterprise downgraded to Sell from Neutral at UBS
UBS analyst John Roy downgraded HP Enterprise to Sell from Neutral and cut his price target for the shares to $13 from $17. The company's on-premises hardware sales are being pressured by the growth in public cloud, while the "stock is expecting better," Roy tells investors in a research note. Further, HP Enterprise's 15%-plus server selling price growth is unlikely to repeat as component prices decline, the analyst adds. He expects the company's revenue growth to decline from 7% in 2018 to negative 2% in 2019. The stock's multiple should contract from 9.5 times to 8.5 times as revenue inflects from growth to decline, Roy contends.
03/12/19
03/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boeing (BA) downgraded to Hold from Buy at Edward Jones. 2. Monster Beverage (MNST) downgraded to Market Perform from Outperform at BMO Capital with analyst Amit Sharma saying Monster's current valuation, both absolute and relative to peers, "may be as good it gets." 3. Coca-Cola (KO) downgraded to Hold from Buy at HSBC with analyst Carlos Laboy saying in "trying to grow the pie," Coke is being required to drive revenues with low-margin brands that may take years to scale up. 4. HP Enterprise (HPE) downgraded to Sell from Neutral at UBS with analyst John Roy saying the company's on-premises hardware sales are being pressured by the growth in public cloud, while the "stock is expecting better." 5. F5 Networks (FFIV) downgraded to Neutral from Overweight at JPMorgan with analyst Samik Chatterjee saying the "expensive" acquisition of NGINX is "tough to digest" given the integration and execution risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DE Deere
$145.97

1.16 (0.80%)

05/16/19
SBSH
05/16/19
NO CHANGE
Target $170
SBSH
Buy
Deere price target lowered to $170 from $180 at Citi
Citi analyst Timothy Thein lowered his estimates for Deere to reflect a "less favorable" agriculture and turf product mix after his early April channel checks pointed to more cautious North America farmer sentiment. Amid a steady stream of negative headlines and incremental weakening in certain key row crop prices, the analyst assumes the greater uncertainty will translate to softer overall row crop farmer spending. Nonetheless, Thein keeps a Buy rating on Deere shares.
05/14/19
JPMS
05/14/19
UPGRADE
Target $77
JPMS
Overweight
Agco upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan upgraded Agco (AGCO) to Overweight from Neutral and raised her price target for the shares to $77 from $66. The analyst coupled the upgrade with a downgrade of Deere (DE) to Underweight from Neutral. Given Agco's limited exposure to the U.S. row crop sector, the recent sell-off in the shares is overdone, Duignan tells investors in a research note. She sees a good entry point at current share levels.
05/14/19
JPMS
05/14/19
DOWNGRADE
Target $132
JPMS
Underweight
Deere downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan downgraded Deere (DE) to Underweight from Neutral and lowered her price target for the shares to $132 from $154. The analyst coupled the downgrade with an upgrade of Agco (AGCO) to Overweight from Neutral. The analyst sees "rapidly deteriorating" fundamentals in U.S. agriculture. Beyond tariffs, Chinese import demand for soybeans is likely to decline significantly as it deals with a ~30% reduction in its hog herd following the outbreak of African swine fever, Duignan tells investors in a research note. Further, Brazil and Argentina combined have produced close to record soybean and corn crops this season, while U.S. dollar strength remains a headwind for U.S. competitiveness on the global market, adds the analyst. She sees a "perfect storm" for U.S. farmers and believes the fundamentals for Deere are now skewed to the downside.
05/14/19
05/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Solid Biosciences (SLDB) downgraded to Underperform from Neutral at Credit Suisse, to Sell from Neutral at Goldman Sachs, and to Neutral from Buy at Chardan. 2. Shopify (SHOP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex citing his view that the stock is not deserving of the same multiple as high-growth U.S. 3. Deere (DE) downgraded to Underweight from Neutral at JPMorgan with analyst Ann Duignan saying she sees "rapidly deteriorating" fundamentals in U.S. agriculture. 4. G-III Apparel (GIII) and Steven Madden (SHOO) downgraded to Neutral from Overweight at Piper Jaffray. 5. Insys Therapeutics (INSY) downgraded to Neutral from Buy at Janney Montgomery Scott. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PINS Pinterest
$26.01

-2.66 (-9.28%)

05/13/19
BARD
05/13/19
INITIATION
Target $36
BARD
Outperform
Pinterest initiated with an Outperform at Baird
Baird analyst Colin Sebastian initiated Pinterest with an Outperform rating and $36 price target, stating that he expects the company to top $1B in revenue this year given its engaged and fast-growing audience and developing ad business. He sees Pinterest having significant runway for growth from international monetization and contributions from shopping/ecommerce as well as operating leverage, Sebastian tells investors.
05/17/19
LEHM
05/17/19
NO CHANGE
Target $28
LEHM
Equal Weight
Pinterest shares likely to trade sideways or down from here, says Barclays
Barclays analyst Ross Sandler says he's not surprised to see shares of Pinterest down 15% following the company's in-line results given the run-up to a 14 times revenue valuation ahead of the print. From here, the analyst expect shares to trade "sideways to down for a bit" until the valuation is "compelling enough compared to its peers." This is somewhere in the low $20s per share, says the analyst, who adds he'd become more constructive on Pinterest at those levels. Sandler has an Equal Weight rating on the name with a $28 price target.
05/13/19
05/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinterest (PINS) initiated with an Outperform at Baird, a Buy at Citi, a Sector Perform at RBC Capital, a Hold at Deutsche Bank, a Neutral at Credit Suisse, UBS, BofA/Merrill, Goldman Sachs, and JPMorgan, and an Equal Weight at Barclays. 2. Zoom Video (ZM) initiated with an Overweight at JPMorgan and Piper Jaffray, a Buy at BofA/Merrill, a Market Perform at Wells Fargo and JMP Securities, a Sector Perform at RBC Capital, a Sector Weight at KeyBanc, an Equal Weight at Morgan Stanley, a Hold at Stifel, and a Neutral at Credit Suisse and Goldman Sachs. 3. Turning Point Therapeutics (TPTX) initiated with an Outperform at Wells Fargo and a Buy at Canaccord and Goldman Sachs. 4. Brigham Minerals (MNRL) initiated with an Overweight at Piper Jaffray and Barclays, an Outperform at Wells Fargo, RBC Capital, and Credit Suisse, and a Buy at Goldman Sachs and UBS. 5. Brainsway (BWAY) initiated with an Outperform at Raymond James and Oppenheimer, a Buy at Ladenburg, and Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/19
BARD
05/17/19
NO CHANGE
Target $36
BARD
Outperform
Pinterest earnings selloff an attractive buying opportunity, says Baird
Baird analyst Colin Sebastian views today's post-earnings selloff in shares of Pinterest as an attractive buying opportunity. The stock in premarket trading is down 15%, or $4.64, to $26.22 following last night's Q1 results. Pinterest reported results confirming the company's preliminary Q1 numbers, with a modest uptick in full-year guidance, Sebastian tells investors in a research note. While some media headlines suggest a revenue and/or earnings miss, this is largely "noise" as a few high-end estimates skewed the consensus, says the analyst. He believes Pinterest's "ongoing strength" in U.S. advertising growth and early signs of traction from its international growth efforts are more important. As such, Sebastian believes the company's fundamentals are intact and he keeps an Outperform rating on the name with a $36 price target.
BIDU Baidu
$138.50

-13.95 (-9.15%)

05/17/19
BNCH
05/17/19
NO CHANGE
Target $180
BNCH
Buy
Baidu price target lowered to $180 from $245 at Benchmark
Benchmark analyst Fawne Jiang reduced her earnings estimates for Baidu to reflect slower revenue growth following the company's "soft" Q1 results and weaker than expected guidance. While Baidu remains focused on strengthening its mobile position and expanding its content and services to revitalize the core marketing business in the near-term, she remains constructive on the company continuing to invest in AI initiatives for longer term growth. Jiang lowered her price target on Baidu shares to $180 from $245 to account for estimate changes, but keeps a Buy rating on the stock, which is down 12% to $135.25 in pre-market trading.
04/23/19
KEYB
04/23/19
NO CHANGE
Target $220
KEYB
Overweight
Baidu price target lowered to $220 from $236 at KeyBanc
KeyBanc analyst Hans Chung lowered his price target for Baidu to $220 from $236 on a higher level of spending in promotions throughout the year and as he anticipates a downward revision on consensus estimates. That said, the analyst also expects ad monetization on incremental traffic growth to materialize in the second half of the year and thus increase the top-line forecast slightly. Chung believes the near-term margin headwinds have been largely priced in and views valuations as attractive. He reiterates an Overweight rating on the shares.
05/17/19
DBAB
05/17/19
DOWNGRADE
DBAB
Hold
Baidu downgraded to Hold from Buy at Deutsche Bank
05/07/19
MZHO
05/07/19
NO CHANGE
Target $205
MZHO
Buy
Baidu price target lowered to $205 from $215 at Mizuho
Mizuho analyst James Lee lowered his price target for Baidu to $205 from $215 saying the company's subsidiary IQ will likely guide revenue below consensus due to the "cleanup of low quality" ad revenues. The analyst, however, keeps a Buy rating on the shares into Baidu's Q1 results.
ADMA ADMA Biologics
$4.32

-0.15 (-3.36%)

10/30/18
HCWC
10/30/18
INITIATION
Target $17
HCWC
Buy
ADMA Biologics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started ADMA Biologics with a Buy rating and $17 price target. ADMA has transformed itself into a fully integrated company with multiple products and a manufacturing operation, all of which should support its original mission, to commercialize RI-002, Kolbert tells investors in a research note.
02/07/19
HCWC
02/07/19
INITIATION
Target $10
HCWC
Buy
ADMA Biologics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of ADMA Biologics with a Buy rating and $10 price target. The analyst believes the current valuation constitutes an attractive entry point. If the FDA accepts its filing, Bivigam could be authorized to re-enter the market within the next few months, says the analyst. ADMA could easily return Bivigam to the sales it had previously reached, exceeding $50M annually, he estimates.
04/04/19
WBBS
04/04/19
UPGRADE
Target $11.5
WBBS
Buy
ADMA Biologics upgraded to Buy from Speculative Buy at WBB Securities
WBB Securities analyst Stephen Brozak upgraded ADMA Biologics to Buy from Speculative Buy after the company received FDA approval for Asceniv, which he views as an important milestone. Brozak raised his price target on ADMA shares to $11.50 from $9.00.
04/15/19
HCWC
04/15/19
NO CHANGE
Target $13
HCWC
Buy
ADMA Biologics price target raised to $13 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ADMA Biologics to $13 from $10 following FDA approval of RI-002. Further, the analyst continues to expect near-term feedback from the FDA on ADMA's response to the Complete Response Letter for Bivigam that the FDA issued in late December 2018. The approval of RI-002 should have favorable implications for the approval of the Bivigam, says the analyst. He reiterates a Buy rating on ADMA Biologics.
UA Under Armour
$19.45

0.5 (2.64%)

05/14/19
COWN
05/14/19
NO CHANGE
COWN
Skechers, G-III among apparel names with outsized tariff risk, says Cowen
Cowen analyst John Kernan said 34% of apparel and about 70% of footwear imported into the U.S. come from China, adding that 25% tariffs on apparel and footwear will create "major disruption" at a time when companies are already facing accelerating disruption from technology and Amazon (AMZN). The analyst, who thinks diversifying from China sourcing will be slow, said he views Skechers (SKX), G-III Apparel (GIII), Carter's (CRI), PVH Corp. (PVH) and Ralph Lauren (RL) as among the apparel stocks with outsized EPS risk. He added that he thinks companies like Under Armour (UAA), that may have lower than sector average exposure to China sourcing but also have lower EBIT margins, as faced with greater sensitivity to higher cost of goods.
05/17/19
JPMS
05/17/19
UPGRADE
Target $29
JPMS
Overweight
JPMorgan upgrades Under Armour to Overweight with $29 price target
JPMorgan analyst Matthew Boss upgraded Under Armour to Overweight from Neutral and raised his price target for the shares to $29 from $23. The shares closed yesterday up 52c to $21.88. After meeting with management including CEO Kevin Plank, Boss says the clear tone from the top was "controlled confidence" in the brand direction with "disciplined" fiscal 2020 global top- and bottom-line growth acceleration. This will be driven by the combination of product, innovation, and marketing after management's three-year strategic "shrink phase" completed exiting fiscal 2019, Boss tells investors in a research note. He believes this translates into a favorable multi-year risk/reward on shares of Under Armour.
04/18/19
PIPR
04/18/19
NO CHANGE
Target $30
PIPR
Overweight
Under Armour Q1 expectations 'at least achievable,' says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says her work year-to-date indicates generally well controlled inventory across the domestic athletic industry. Currently, Under Armour (UAA) online clearance styles are down 19% year-over-year versus Nike's (NKE) down 5% and Adidas' (ADDYY) up 96%. The analyst believes industry competition "should remain rational" during 2019. Further, Q1 consensus expectations for Under Armour are "at least achievable" and management should maintain fiscal 2019 guidance, Murphy tells investors in a pre-earnings research note. The analyst this quarter has seen on-going traction with HOVR's footwear platform, broader focus with Under Armour's women's and a well-supported launch of Rush. She keeps an Overweight rating on Under Armour shares with a $30 price target.
05/17/19
JPMS
05/17/19
UPGRADE
Target $29
JPMS
Overweight
Under Armour upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Matthew Boss upgraded Under Armour to Overweight from Neutral and raised his price target for the shares to $29 from $23.
UAA Under Armour
$22.04

0.68 (3.18%)

ACHN Achillion
$3.05

0.005 (0.16%)

12/13/18
JMPS
12/13/18
NO CHANGE
Target $10
JMPS
Outperform
JMP says Achillion oral factor D update could renew interest in stock
JMP Securities analyst Liisa Bayko noted that Achillion's oral factor D inhibitor studies have been slow to enroll due to limited trial sites, but the company plans to update investors on its oral factor D portfolio this coming Monday, which she believes has the potential to renew interest in the stock. She is looking for updated data from first-gen oral factor D inhibitor ACH-4471 from four ongoing studies and the first Phase 1 data from next-gen factor D inhibitors, ACH-5228 and ACH-5548, adding that data that support activity in the C3G indication or in PNH "could reinvigorate interest." Bayko, who sees a blockbuster opportunity for an oral product in this category, keeps an Outperform rating and $10 price target on Achillion shares.
05/03/19
05/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yeti (YETI) downgraded to Neutral from Buy at Goldman Sachs with analyst Alexandra Walvis saying the company's "strong" sales and brand momentum are now better understood by investors. 2. Electronic Arts (EA) downgraded to Neutral at MKM Partners on valuation with analyst Eric Handler saying the risk-reward on the stock appears to be "less compelling." 3. Cognizant (CTSH) downgraded to Market Perform from Outperform at William Blair, to Underweight from Neutral at JPMorgan, to Neutral from Buy at Goldman Sachs, to Perform from Outperform at Oppenheimer, to Sector Weight from Overweight at KeyBanc, to Neutral from Outperform at Wedbush and to Hold from Strong Buy at Needham after the company's earnings and guidance missed consensus estimates. 4. Target (TGT) downgraded to Market Perform from Outperform at Bernstein with analyst Brandon Fletcher saying he thinks Target's continued emphasis on growth over cost containment is a "less wise" stance at this point. 5. Achillion (ACHN) downgraded to Underweight from Equal Weight at Barclays with analyst Geoffrey Meacham seeing a lack of near- to mid-term catalysts that are capable of changing the story on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
LEHM
05/03/19
DOWNGRADE
Target $2.5
LEHM
Underweight
Achillion downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham downgraded Achillion Pharmaceuticals to Underweight from Equal Weight and cut his price target for the shares to $2.50 from $5.
05/03/19
LEHM
05/03/19
DOWNGRADE
Target $2.5
LEHM
Underweight
Barclays downgrades Achillion to Underweight on lack of data catalysts
Barclays analyst Geoffrey Meacham downgraded Achillion Pharmaceuticals to Underweight from Equal Weight and cut his price target for the shares to $2.50 from $5. The analyst sees a lack of near- to mid-term catalysts that are capable of changing the story on the stock. He notes the downgrade has less to do with the underlying fundamentals of Achillion's Factor D program.
MTNB Matinas BioPharma
$0.94

0.0228 (2.48%)

09/24/18
MAXM
09/24/18
NO CHANGE
Target $2
MAXM
Buy
Amarin's Vascepa outcomes trial positive for Matinas, says Maxim
Maxim analyst Jason McCarthy notes that Amarin (AMRN) released clinical trial data showing that Vascepa significantly reduced the risk of major CV events by 25% compared to placebo. The most important takeaway is that these patients already had LDL cholesterol controlled with a statin, he contends. The analyst believes this directly impacts Matinas (MTNB) as it also has a prescription omega-3 fatty acid, MAT9001, which is potentially superior to Vascepa. Further, McCarthy argues that the outcomes study could change the conversation for partnering opportunities for MAT9001. Overall, the analyst believes the news is a significant positive for Matinas, and reiterates a Buy rating and $2 price target on the shares.
11/13/18
MAXM
11/13/18
NO CHANGE
Target $5
MAXM
Buy
Matinas BioPharma price target raised to $5 from $2 at Maxim
Maxim analyst Jason McCarthy raised his price target on Matinas BioPharma (MTNB) to $5 and kept his Buy rating after its Q3 results. The analyst adds that he is also factoring in the impact of MAT9001 after the outcome of data evaluating Amarin's (AMRN) Vascepa + Statin, and the company's decision to move MAT9001 forward for hypertriglyceridemia.
05/17/19
BTIG
05/17/19
INITIATION
Target $5
BTIG
Buy
Matinas BioPharma initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Matinas BioPharma (MTNB) with a Buy rating and $5 price target, noting that the company's lead candidate, MAT9001, showed superior TG lowering versus Amarin's(AMRN) Vascepa. He thinks the Omega 3 class can have multiple winners and estimates MAT9001 peak revenue of greater than $2B.
02/11/19
ROTH
02/11/19
INITIATION
Target $4.75
ROTH
Buy
Matinas BioPharma initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson started coverage of Matinas BioPharma with a Buy rating and a $4.75 price target. The analyst assumes MAT9001 approval for hypertriglyceridemia in 2023 and pricing starting at $1,100 annually per patient.
AMAT Applied Materials
$44.28

2.78 (6.70%)

05/15/19
SUSQ
05/15/19
UPGRADE
Target $60
SUSQ
Positive
Applied Materials upgraded to Positive on 'major' memory wins at Susquehanna
Susquehanna analyst Mehdi Hosseini upgraded Applied Materials to Positive from Neutral, stating that his recent checks suggest that the company has won "major" memory design wins that should help it regain lost share and put it back on track for an "annualized" EPS run rate of $5 in the second half of 2020. The analyst, who also said he believes semi cap fundamentals are "not far from a bottoming," raised his price target on Applied shares to $60 from $34.
05/15/19
SUSQ
05/15/19
UPGRADE
Target $82
SUSQ
Positive
Susquehanna upgrades Advanced Energy to Positive on Applied Materials gains
As previously reported, Susquehanna analyst Mehdi Hosseini upgraded Advanced Energy (AEIS) to Positive from Neutral, stating that he believes the company is poised to benefit from market share gains made by its largest customer, Applied Materials (AMAT). As Hosseini told investors in his separate upgrade of Applied Materials to Positive, his recent checks suggest that the company has won "major" memory design wins that should help it regain lost share. He thinks Applied gaining memory share is "particularly positive" for Advanced's semi system business unit, the analyst stated. Hosseini raised his price target on Advanced Energy shares to $82 from $45.
05/15/19
05/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) upgraded to Buy from Neutral at Goldman Sachs with analyst Robert Koort saying the stock's 49% decline over the past year has created an opportunity to gain exposure to two commodity cycles that are bottoming, ethylene and chloralkali. 2. Zillow (ZG, Z) upgraded to Buy from Neutral at Guggenheim with analyst Jake Fuller saying its recent results prove that demand for Offers "is real" and he expects the company's Offers business to surpass its ad business by Q4 and generate greater than $1B of revenue in its first full year. 3. Chevron (CVX) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Neil Mehta saying Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. 4. Hess Corp. (HES) upgraded to Equalweight from Underweight at Capital One with analyst Phillips Johnston saying he reviewed his model post Q1 earnings and "massively" overhauled his Guyana production estimates. 5. Applied Materials (AMAT) and Advanced Energy (AEIS) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/19
RILY
05/17/19
UPGRADE
Target $54
RILY
Buy
Applied Materials upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Craig Ellis upgraded Applied Materials to Buy from Neutral and raised his price target for the shares to $54 from $46. Signs of a recovery are starting to emerge following the company's better than expected fiscal Q2 results, Ellis tells investors in a research note.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$37.54

-0.35 (-0.92%)

, S

Sprint

$7.01

0.2 (2.94%)

18:08
06/14/19
06/14
18:08
06/14/19
18:08
Periodicals
Dish leads bidding for Sprint, T-Mobile assets, WSJ reports »

Dish Network (DISH) is…

DISH

Dish

$37.54

-0.35 (-0.92%)

S

Sprint

$7.01

0.2 (2.94%)

TMUS

T-Mobile

$74.90

0.44 (0.59%)

CHTR

Charter

$392.20

2.76 (0.71%)

ATUS

Altice USA

$23.82

0.15 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$32.69

-0.39 (-1.18%)

17:31
06/14/19
06/14
17:31
06/14/19
17:31
Periodicals
American Air asks court to end 'devastating' work slowdown, Bloomberg says »

American Airlines urged a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROLL

RBC Bearings

$150.43

-3.38 (-2.20%)

17:16
06/14/19
06/14
17:16
06/14/19
17:16
Hot Stocks
RBC Bearings CEO sells over 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$1.25

(0.00%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
FTE Networks granted financial viability exception by NYSE regulation »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.19

-1.54 (-0.44%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
Boeing awarded Air Force contract modification, increases ceiling by $6.53B »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

MDR

McDermott

$7.60

-0.12 (-1.55%)

17:11
06/14/19
06/14
17:11
06/14/19
17:11
Hot Stocks
Chatterjee Fund Management reports 5.6% passive stake in McDermott »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$50.74

0.28 (0.55%)

17:09
06/14/19
06/14
17:09
06/14/19
17:09
Hot Stocks
Papa John's dismisses KPMG as auditors, hires Ernst & Young »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

EPZM

Epizyme

$11.62

-0.36 (-3.01%)

16:55
06/14/19
06/14
16:55
06/14/19
16:55
Conference/Events
Epizyme to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

CACI

CACI

$202.80

-1.205 (-0.59%)

16:54
06/14/19
06/14
16:54
06/14/19
16:54
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HCR

Hi-Crush Inc.

$2.84

0.115 (4.22%)

16:53
06/14/19
06/14
16:53
06/14/19
16:53
Syndicate
Hi-Crush Inc files $1B mixed securities shelf »

The company also files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHIP

Seanergy Marine

$0.63

-0.0381 (-5.70%)

16:51
06/14/19
06/14
16:51
06/14/19
16:51
Earnings
Seanergy Marine reports Q1 EPS ($3.23), two estimates ($2.85) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.